Solid Biosciences (SLDB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, at 8:00 AM ET, to be held virtually.
Shareholders are encouraged to review proxy materials and vote in advance or during the meeting.
Voting matters and shareholder proposals
Election of three Class II directors: Clare Kahn, Adam Stone, and Lynne Sullivan, with board recommendation to vote for all.
Advisory ratification of llan Ganot as a Class I Director until the 2028 annual meeting.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of an amendment to increase authorized common stock from 240,000,000 to 480,000,000 shares.
Advisory vote on executive compensation.
Board of directors and corporate governance
Board recommends all director nominees and advisory appointments.
Proxies are authorized to vote on other business as may arise during the meeting.
Latest events from Solid Biosciences
- Stockholders will vote on director elections, auditor ratification, share increase, and executive pay.SLDB
Proxy filing23 Apr 2026 - Gene therapy programs show strong safety, efficacy, and innovation, with key data readouts ahead.SLDB
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Virtual meeting to vote on directors, auditor, share increase, and executive pay; board supports all.SLDB
Proxy filing10 Apr 2026 - Strong clinical progress and $240M financing extend cash runway into 2028 despite higher net loss.SLDB
Q4 202520 Mar 2026 - 42.8 million shares registered for resale after a $240M private placement in gene therapy.SLDB
Registration filing19 Mar 2026 - Registering 1.3M shares for resale after asset acquisition; no proceeds to the company.SLDB
Registration filing19 Mar 2026 - Gene therapy trials for DMD and FA advance with FDA alignment and innovative delivery methods.SLDB
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - SGT-003 interim data showed strong efficacy; Q3 net loss $45.8M, cash runway into H1 2027.SLDB
Q3 202510 Feb 2026 - Net loss widened to $39.5M in Q2 2025 as R&D surged; cash runway extends into 2027.SLDB
Q2 202510 Feb 2026